Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220002/S009

TOPS System

Premia Spine, Ltd. · Decision date May 29, 2026

FDA DECISIONP220002/S009

What did the FDA approve?

FDA records P220002/S009 as a supplement to PMA P220002, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 29, 2026.

FDA approval order statement

Approval for the addition of a new inserter (TOPS 2 inserter) and implant design variant (TOPS 2) to be included in the TOPS System
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Orthopedic
Decision date
May 29, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P220002/S009
Regulatory pathway
PMA supplement
Product code
QWK
Decision code
APPR
Decision date
May 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, posterior spinal elements.

Product code
QWK
FDA device class
3

For the original device and its historical approval scope, see PMA P220002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P220002/S009 received

    Application receipt date recorded by FDA.

  2. P220002/S009 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P220002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220002

Product / regulatory recordCompanyPathwayDecision dateSource
Premia Spine, Ltd.PMA approvalJun 15, 2023FDA
TOPS SystemP220002/S010
Premia Spine, Ltd.PMA supplementOct 29, 2025FDA
TOPS SystemP220002/S011
Premia Spine, Ltd.PMA supplementSep 9, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Premia Spine, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7 Giborey Israel St., Ramat Poleg, Netanya, 4250407

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records